Inter Pipeline Ltd. (IPPLF) Financials Nov 14, 2014, 4:03
Inter Pipeline Ltd. (IPPLF) Financials Nov 14, 2014, 4:03 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Inter Pipeline Ltd.
Fiscal year is January-December. All values CAD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 924.55M 995.07M 1.18B 1.19B 1.35B
Cost of Goods Sold (COGS) incl. D&A 650M 643.03M 655.46M 648.94M 779.48M
COGS excluding D&A 547.78M 555.49M 555.74M 524.34M 650.89M
Depreciation & Amortization Expense 102.23M 87.54M 99.72M 124.59M 128.59M
Depreciation 88.08M 73.4M 85.6M 98.17M 107.58M
Amortization of Intangibles 14.15M 14.14M 14.12M 26.42M 21.01M
Gross Income 274.55M 352.04M 526.84M 544.47M 570.69M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 41.44M 52.92M 65.47M 83.41M 85.04M
Research & Development 0 - 0 - -
Other SG&A 41.44M 52.92M 65.47M 83.41M 85.04M
Other Operating Expense 6.99M 0 0 0 0
Unusual Expense 65.23M 3.57M 14.54M (44.36M) 357.65M
EBIT after Unusual Expense (65.23M) (3.57M) (14.54M) 44.36M (357.65M)
Non Operating Income/Expense 17.84M (12.48M) (36.25M) 1.74M 5.99M
Non-Operating Interest Income 0 - - 0 0
Equity in Affiliates (Pretax) 0 0 0 - -
Interest Expense 36.93M 42.97M 82.36M 100.88M 94.39M
Gross Interest Expense 36.93M 42.97M 83.61M 106.55M 120.71M
Interest Capitalized 0 0 1.26M 5.67M 26.32M
Pretax Income 141.79M 240.1M 328.22M 406.28M 39.6M
Income Tax (15.89M) 5.33M 80.29M 89.3M 86.6M
Income Tax - Current Domestic 791,000 1.44M 51.59M 56.28M 56.33M
Income Tax - Current Foreign 0 0 0 767,000 786,000
Income Tax - Deferred Domestic (16.68M) 3.89M 28.7M 36.03M 37.09M
Income Tax - Deferred Foreign 0 0 0 (3.78M) (7.6M)
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 - -
Other After Tax Income (Expense) 0 - 0 0 0
Consolidated Net Income 157.68M 234.77M 247.93M 316.98M (47M)
Minority Interest Expense 0 0 0 9.83M 11.1M
Net Income 157.68M 234.77M 247.93M 307.15M (58.1M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 157.68M 234.77M 247.93M 307.15M (58.1M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 157.68M 234.77M 247.93M 307.15M (58.1M)
EPS (Basic) 0.66 0.91 0.95 1.14 (0.20)
Basic Shares Outstanding 238.06M 256.88M 260.95M 269.9M 285.94M
EPS (Diluted) 0.66 0.91 0.95 1.14 (0.20)
Diluted Shares Outstanding 238.8M 257.04M 260.95M 270.59M 285.94M
EBITDA 328.35M 386.65M 561.09M 585.65M 614.24M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...
Continue Reading
Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...
Continue Reading
Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....
Continue Reading
Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...
Continue Reading
A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...
Continue Reading
Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...
Continue Reading
Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...
Continue Reading
A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...
Continue Reading
Top 5 Most Recently Viewed Articles
BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...
Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...
Continue Reading
New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...
Continue Reading
Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...
Continue Reading
BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...
Continue Reading